Lantheus Holdings (FRA:0L8) Days Sales Outstanding : 76.55 (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Lantheus Holdings Days Sales Outstanding?

Lantheus Holdings's average Accounts Receivable for the three months ended in Mar. 2024 was €286 Mil. Lantheus Holdings's Revenue for the three months ended in Mar. 2024 was €340 Mil. Hence, Lantheus Holdings's Days Sales Outstanding for the three months ended in Mar. 2024 was 76.55.

The historical rank and industry rank for Lantheus Holdings's Days Sales Outstanding or its related term are showing as below:

FRA:0L8' s Days Sales Outstanding Range Over the Past 10 Years
Min: 42.45 Med: 48.86 Max: 73.73
Current: 73.73

During the past 13 years, Lantheus Holdings's highest Days Sales Outstanding was 73.73. The lowest was 42.45. And the median was 48.86.

FRA:0L8's Days Sales Outstanding is ranked worse than
51.55% of 999 companies
in the Drug Manufacturers industry
Industry Median: 72.15 vs FRA:0L8: 73.73

Lantheus Holdings's Days Sales Outstanding increased from Mar. 2023 (69.44) to Mar. 2024 (76.55).

Lantheus Holdings Days Sales Outstanding Historical Data

The historical data trend for Lantheus Holdings's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lantheus Holdings Days Sales Outstanding Chart

Lantheus Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

45.32

54.66

59.87

58.00

70.94

Lantheus Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Sales Outstanding	Get a 7-Day Free Trial															69.44	71.09	72.96	70.78	76.55

Competitive Comparison of Lantheus Holdings's Days Sales Outstanding

For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lantheus Holdings's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Lantheus Holdings's Days Sales Outstanding falls into.

Lantheus Holdings Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Lantheus Holdings's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (201.447	+	260.696)	/	2 )	/	1188.825	*	365
=	231.0715					/	1188.825	*	365
=	70.94

Lantheus Holdings's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding (Q: Mar. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Mar. 2024 ))	/	count )	/	Revenue (A: Mar. 2024 )	*	Days in Period
=	( (260.696	+	310.398)	/	2 )	/	340.377	*	365 / 4
=	285.547					/	340.377	*	365 / 4
=	76.55

Lantheus Holdings (FRA:0L8) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Lantheus Holdings Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Lantheus Holdings's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Lantheus Holdings (FRA:0L8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lantheus Holdings Inc (FRA:0L8) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

LNTH:USA 0L8:Germany

Address

201 Burlington Road, South Building, Bedford, MA, USA, 01730

Website

https://www.lantheus.com

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Lantheus Holdings (FRA:0L8) Headlines

No Headlines